J&J CEO: No Entry into GLP-1 Weight Loss Drugs, Aiming to Be World's #1 in Oncology by 2030
Alina Collins
J&J CEO Joaquin Duato publicly ruled out entering the GLP-1 weight-loss market, naming oncology and neuroscience as the company's core pillars with a target to become the world's number-one cancer company by 2030 — the clearest contrarian bet yet amid the obesity-drug boom.
Everyone is chasing weight-loss drugs — why is J&J sitting out?
CEO Duato stated it plainly at the Washington Economic Club: "We will not enter the GLP-1 space."
This means → while Eli Lilly and Novo Nordisk drive a GLP-1 (a class of drugs that suppress appetite and reduce body weight) gold rush, J&J is deliberately choosing not to follow.
In plain terms = the industry is piling into the hottest trend in pharma, and J&J is saying "that's not our fight" — keeping its resources for higher-conviction bets.
Where is the money going? Cancer and brain disease
Duato named oncology and neuroscience as J&J's two core growth pillars, with the goal of becoming "the world's number-one cancer company by 2030."
On the cancer side: J&J already leads in multiple myeloma — a bone-marrow cancer — and is building a lung-cancer pipeline. In 2025 it paid $3.05 billion in cash for Halda Therapeutics, acquiring an innovative oral prostate-cancer therapy.
On the neuroscience side: Duato called neurodegenerative disease "the most important problem," pledging continued investment despite earlier R&D setbacks.
What did J&J cut to sharpen its focus?
The company spun off its consumer-health unit Kenvue (home to Tylenol, Band-Aid, and Johnson's Baby) and divested its slower-growth orthopedics business.
This means → J&J stripped out its best-known household brands and low-growth segments, keeping only the medical-innovation core.
The result: a 47% total shareholder return in 2025 — one of the strongest years in J&J's history.
Are AI and robotic surgery the next growth lever?
Duato sees artificial intelligence accelerating drug discovery and boosting medical-device performance, with particular promise in robotic surgery.
He positioned J&J as being in "the early stages of a new growth cycle."
This reflects a bet beyond the near-term oncology pipeline — J&J is wagering that technological change will amplify its R&D and device advantages.
Is this strategy the right call? What should investors watch?
J&J's logic is clear: skip the trend, double down on existing strengths, cut everything that dilutes focus.
In plain terms = this is a subtraction strategy — a bet that depth is worth more than breadth.
The key test: whether J&J can deliver on its "world number one" promise in both oncology and neuroscience by 2030.
Content is for reference only, not financial advice.